On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
BUSINESS
Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
Sosei Group’s unique drug discovery platform for G protein-coupled receptor (GPCR)-targeted compounds is attracting a growing list of big pharma companies, with CEO Shinichi Tamura stressing that small molecules are still “the high road” in pharmaceuticals despite drug makers’ uphill…
To read the full story
Related Article
- Sosei Regains Global Rights to Muscarinic Agonist Programs from AbbVie, CEO Says It’s Not Bad News
January 6, 2021
- Sosei, Pfizer Nominate 3rd Development Candidate Compound
December 25, 2019
- Sosei Bags US$3 Million from Genentech on Nomination of New GPCR Disease Target
October 10, 2019
- Sosei, Takeda Seal Multi-Target Collaboration Deal
August 6, 2019
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
BUSINESS
- Chugai’s FoundationOne Approved as CDx for Larotrectinib in Japan
January 26, 2021
- Health Damages Linked to Kobayashi Kako Mix-Up Rise to 215
January 26, 2021
- Mitsubishi Tanabe Gets US Commercial Rights for Aquestive’s ALS Med
January 25, 2021
- Shipment Control Triggered for Bayer’s Stivarga on Overseas Delay
January 25, 2021
- Chugai, Taisho to Wind Up Edirol Sales Collaboration in April
January 25, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…